What You Should Know:
– Viz.ai, a San Francisco-based AI-powered disease detection and care coordination platform raises $1000M in Series D funding led by Tiger Global and Insight Partners. The round also included participation from Scale Ventures, Kleiner Perkins, Threshold, GV (formerly Google Ventures), Sozo Ventures, CRV, and Susa.
– The new funds will be used to support Viz.ai’s significant growth trajectory, expand the Viz Platform to detect and triage additional diseases, and grow its customer base globally.
Platform Accelerating Access to Life Savings Treatments
Through its AI-powered disease detection and c the company is changing the way diseases are diagnosed and treated with AI that works within physician workflows, increasing diagnostic rates and speeding treatment. Now, it is expanding into life sciences to broaden the continuum of care with a groundbreaking AI-driven life science platform, a first-of-its-kind solution that revolutionizes the way medical device and pharmaceutical companies perform clinical trials and bring their treatments to market. Viz.ai has signed partnerships with several of the world’s largest life science companies who look to digital health to complement and enhance traditional efforts.
The funding announcement follows the launch of Viz.ai’s groundbreaking AI-driven life science platform, a first-of-its-kind solution that revolutionizes the way medical device and pharmaceutical companies perform clinical trials and bring their treatments to market. Viz.ai has signed partnerships with several of the world’s largest life science companies. These companies are paying close attention as they increasingly look to digital health to complement and enhance traditional efforts.
Recent Growth & Milestones
Viz.ai continues to expand its reach and innovation in additional disease states. Through its vast network of hospital and health system customers, Viz.ai assists in the care of one patient every 32 seconds. Over the past year, Viz.ai launched AI-driven solutions for aortic disease, pulmonary embolism, cerebral aneurysms, and is 510(k) pending for subdural hematoma. Viz.ai has seen great momentum in Europe, Middle East and Africa, with the company being awarded its first five CE Marks in 2021, followed by contracts with several leading hospitals. Viz.ai is hiring the best and brightest clinical, product, engineering and business minds to support and fuel its growth. With locations in San Francisco, Tel Aviv, Portugal and Amsterdam, the Viz.ai team has grown from 180 to more than 350 over the past 12 months, and is planning to grow by nearly 200 people over the next 12 months.
